Home › Compare › JSGCF vs ABBV
JSGCF yields 5.07% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, JSGCF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JSGCF + ABBV for your $10,000?
LIXIL Corporation, through its subsidiaries, manufactures and sells building materials and housing equipment worldwide. It operates through LIXIL Water Technology (LWT), LIXIL Housing Technology (LHT), LIXIL Building Technology (LBT), and Housing & Services Business (H&S) segments. The LWT segment offers sanitary ware, shower toilets, water faucets, washstands, bathtubs, prefabricated bathrooms, smart products, showerheads, washstand fixtures, washstand cabinet units, kitchen systems, etc.; and tiles for houses and buildings, and internal decorative tiles, etc. This segment offers its products under the INAX, GROHE, American Standard, COBRA, DXV, Jaxson, RICHELLE, and SPAGE brands. The LHT segment provides housing window sashes, entrance doors, various types of shutters, gates, carports, banisters, high railings, etc.; window frames, wooden furnishing materials, interior decorative materials, etc.; sidings, roofing materials, etc.; and solar power systems, etc. This segment offers its products under the Tostem, Exsior, Interio, Super Wall, Nodea, and Asahi Tostem brands. The LBT segment offers curtain walls, building window sashes, store facades, etc. The H&S segment engages in the development of homebuilding franchise chains, construction on order, etc.; and provides services for land, buildings, real estate management, real estate franchises development support, etc., as well as housing loans. This segment offers its products under the Lixil, Eyeful Home, Face Home, ERA, and GL HOME brands. The company was formerly known as LIXIL Group Corporation and changed its name to LIXIL Corporation in December 2020. LIXIL Corporation was founded in 1875 and is headquartered in Tokyo, Japan.
Full JSGCF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.